Researchers design ‘prodrug’ that targets cancer cells’ big appetite for glutamine, leaving healthy cells unharmed

Johns Hopkins Medicine researchers have revamped an anti-cancer drug to better target cancer cells and leave healthy tissues unharmed. Scientists have dubbed this type of targeted approach a “prodrug”—a medicine designed to release its payload in a particular area of the body and in no other areas.